Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma

导出原文传递

翻译打印收藏纠错

作者： Kawachi, Hayato ^[1] ; Kunimasa, Kei ^[2] ; Kukita, Yoji ^[3] ; Nakamura, Harumi ^[4] ; Honma, Keiichiro ; Kawamura, Takahisa ; Inoue, Takako ; Tamiya, Motohiro ; Kuhara, Hanako ; Nishino, Kazumi ; Mizote, Yu ; Akazawa, Takashi ; Tahara, Hideaki ; Kumagai, Toru

作者单位： Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan ^[1] Osaka Int Canc Inst, Lab Genom Pathol, Osaka, Japan ^[2] Osaka Int Canc Inst, Dept Canc Drug Discovery Dev, Osaka, Japan ^[3] Osaka Int Canc Inst, Dept Diagnost Pathol Cytol, Osaka, Japan ^[4]

关键词 atezolizumab bevacizumab immunotherapy SMARCA4-DTS SMARCA4-DTST

发布时间 2021-09-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交